Industry Briefs: October 22, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
AMRI has extended its API supply agreement with Shire. Read More
Aptuit has announced the offering of antibacterial studies from a single site, the Aptuit Center for Drug Discovery & Development in Verona, Italy.
The National Institute of Allergy and Infectious Diseases has awarded Pfenex a contract to develop an alternative delivery method for its recombinant protective antigen (rPA)-based anthrax vaccine. Read More
Pluristem Therapeutics has achieved a milestone towards the completion of its new GMP manufacturing facility for commercial production of the company’s Placental eXpanded cells. Read More
The United States Pharmacopeial Convention (USP) has selected the Thermo Scientific TruScan RM and microPHAZIR RX instruments to support its recent initiative to provide USP-approved spectral libraries to pharmaceutical manufacturers. Read More
People News
AMRI has appointed Steven R. Hagen as senior vice-president of pharmaceutical development and manufacturing. Read More
Cobra Biologics has appointed John Birch, former chief scientific officer for Lonza Biopharmaceuticals, as a nonexecutive director. Read More
ISPE has announced its 2012–2013 board of directors election results, including Charlotte Enghave Fruergaard as chair and Damian Greene as vice-chair. Read More
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
